ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2026
Summary of the National Advisory Committee on Immunization (NACI) rapid response: Updated guidance on the use of Imvamune® for the prevention of mpox.
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The National Advisory Committee on Immunization (NACI) previously released guidance in May of 2024 regarding the use of Imvamune® for the prevention of mpox in the context of a routine immunization program. Since the release of this guidance, the emergence of a novel subclade of mpox (clade Ib) has led to a shifting epidemiological landscape and several international jurisdictions have, therefore, revised their Imvamune guidance. Objective: To summarize the updated NACI guidance on the use of Imvamune for the prevention of mpox. Methods: NACI reviewed data on the current epidemiology of mpox, both in Canada and internationally, current evidence on Imvamune vaccination coverage in Canada, and published scientific literature regarding the effectiveness, immunogenicity and safety of Imvamune. NACI has also considered additional factors including ethics, equity, feasibility and acceptability. Guidance on the use of Imvamune in the context of international travel was developed in collaboration with the Canadian Committee to Advise on Tropical Medicine and Travel. Results: NACI concluded that available evidence supports the limited expansion of groups considered at high risk of mpox. Conclusion: NACI now recommends that in addition to previously identified groups at high risk of mpox, certain travellers to areas with ongoing community transmission of mpox virus clade I should receive Imvamune. Healthcare workers travelling internationally to support mpox outbreaks should also receive Imvamune, and domestic healthcare workers with a high risk of frequent exposure may consider vaccination with Imvamune on an individual basis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.